olivLaw · US equity research
IM Cannabis Corp. IMCC
Medicinal Chemicals & Botanical Products · SIC 2833 · Vertical: Medicinal Chemicals & Botanical Products (SIC 2833)
IM Cannabis Corp. imports, distributes and sells medical cannabis to patients in Israel and Germany, using a cross-border supply chain. In 2025 Germany became the main market after the access reforms of April 2024, but the company still does not make a profit and continuing operations depends on additional funding. Total revenue was 54.7 million CAD, while the operating loss was 11.6 million USD.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, IM Cannabis Corp. (IMCC) stock was 0.72 USD (−0.99% on the day), with beta 0.69, 52-week range 0.72–56.40 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 29.9
- oversold (≤ 30)
- Bollinger (20, 2)
- 0.49 – 1.77
- in the lower half of the band · %B 0.18 · band width 113.3%
- SMA 50 / 200
- 1.96 / 10.74
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.39 / -0.40
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −63.1% | −1.1% | −62.0 pp | — |
| 3 months | −81.2% | −0.5% | −80.7 pp | — |
| 6 months | −90.7% | +4.4% | −95.1 pp | — |
| Year to date | −98.3% | +12.3% | −110.6 pp | — |
| 1 year | −98.1% | +13.5% | −111.7 pp | −35.8% |
| 3 years | −99.2% | +76.4% | −175.6 pp | −14.7% |
| 5 years | −100.0% | +63.7% | −163.7 pp | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
the price (USD) and the reports are in different currencies
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2019 | 2020 | ⚠ 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 9.1 m | 15.9 m | 34.1 m | 54.3 m | 48.8 m | 54.0 m | 54.7 m |
| Revenue YoY | unavailable | +75.1% | — | +59.6% | −10.2% | +10.7% | +1.3% |
| Net income | -7.3 m | -28.7 m | -17.8 m | -188.9 m | -9.5 m | -10.6 m | -11.3 m |
| Net income YoY | unavailable | unavailable | — | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | -1.90 | -6.70 | -161.88 | -4.45 | -4.51 | unavailable |
| Diluted EPS YoY | unavailable | unavailable | — | unavailable | unavailable | unavailable | unavailable |
| net % | -80.4% | -180.6% | -52.2% | -347.6% | -19.5% | -19.6% | -20.7% |
| Free cash flow | -7.5 m | -10.5 m | -39.0 m | -14.2 m | -8.7 m | -1.2 m | 4.7 m |
The series breaks before 2021: earlier years come from the original reports of the issuer of that time, later years from a subsequent filing that restated the perimeter (a separation, discontinued operations). The year-on-year change across the break is not shown.
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 2.7 m CAD
- Financial debt
- 15.3 m CAD
- Net debt
- 12.5 m CAD
- Equity
- -3.6 m CAD
- Total assets
- 31.7 m CAD
- Debt / equity
- unavailable
- Current ratio
- 0.67x
- ROE
- unavailable
- ROA
- -31.9%
- FCF margin
- 8.6%
Financial statements (source on every figure)
Revenue and net income (CAD)
Margins
Income statement · CAD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 15.9 m | 34.1 m | 54.3 m | 48.8 m | 54.0 m | 54.7 m | SEC (XBRL)· 30 Mar 2026verified |
| Cost of revenue | 7.1 m | 25.5 m | 43.0 m | 38.0 m | 45.6 m | 45.0 m | SEC (XBRL)· 30 Mar 2026verified |
| Gross profit | 10.5 m | 6.3 m | 9.2 m | 9.8 m | 8.5 m | 9.7 m | SEC (XBRL)· 30 Mar 2026verified |
| Research & development | 136.0 k | — | — | — | — | — | SEC (XBRL)· 19 May 2021verified |
| Operating income | -8.2 m | -23.0 m | -30.8 m | -12.8 m | -10.2 m | -11.6 m | SEC (XBRL)· 30 Mar 2026verified |
| Depreciation & amortisation | 930.0 k | 2.1 m | 2.8 m | — | — | — | SEC (XBRL)· 29 Mar 2023verified |
| EBITDA | -7.3 m ≈ | -20.9 m ≈ | -28.0 m ≈ | — | — | — | SEC (XBRL)· 29 Mar 2023derived |
| Interest expense | 20.5 m | 673.0 k | 2.0 m | 3.7 m | 4.8 m | 3.5 m | SEC (XBRL)· 30 Mar 2026verified |
| Pre-tax income | -28.5 m | -164.0 k | -26.1 m | -9.5 m | -12.8 m | -11.7 m | SEC (XBRL)· 30 Mar 2026verified |
| Income tax | 262.0 k | 500.0 k | -1.1 m | 771.0 k | -1.0 m | 92.0 k | SEC (XBRL)· 30 Mar 2026verified |
| Net income | -28.7 m | -17.8 m | -188.9 m | -9.5 m | -10.6 m | -11.3 m | SEC (XBRL)· 30 Mar 2026verified |
| Diluted EPS | -1.90 | -6.70 | -161.88 | -4.45 | -4.51 | — | SEC (XBRL)· 31 Mar 2025verified |
| Weighted average diluted shares | 38.6 m | 6.0 m | 7.5 m | 12.8 m | — | — | SEC (XBRL)· 28 Mar 2024verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · CAD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 8.9 m | 13.9 m | 2.4 m | 1.8 m | 863.0 k | 2.7 m | SEC (XBRL)· 30 Mar 2026verified |
| Receivables | 689.0 k | 14.5 m | 3.3 m | 4.8 m | 5.4 m | 4.3 m | SEC (XBRL)· 30 Mar 2026verified |
| Inventories | 8.4 m | 29.4 m | 16.6 m | 10.0 m | 3.2 m | 4.3 m | SEC (XBRL)· 30 Mar 2026verified |
| Current assets | 27.1 m | 81.2 m | 32.7 m | 24.3 m | 23.4 m | 22.7 m | SEC (XBRL)· 30 Mar 2026verified |
| Property, plant & equipment, net | 5.5 m | 30.3 m | 5.2 m | 5.1 m | 3.7 m | 3.7 m | SEC (XBRL)· 30 Mar 2026verified |
| Goodwill | 304.0 k | 121.3 m | 9.8 m | 10.1 m | 6.7 m | 1.9 m | SEC (XBRL)· 30 Mar 2026verified |
| Intangibles (excl. goodwill) | 1.1 m | 30.9 m | 7.9 m | 5.8 m | 3.3 m | 1.2 m | SEC (XBRL)· 30 Mar 2026verified |
| Total assets | 38.1 m | 287.4 m | 60.7 m | 48.8 m | 39.2 m | 31.7 m | SEC (XBRL)· 30 Mar 2026verified |
| Short-term debt | 0 | 9.5 m | 9.2 m | 12.1 m | 15.1 m | 14.3 m | SEC (XBRL)· 30 Mar 2026verified |
| Long-term debt | 0 | 392.0 k | 399.0 k | 394.0 k | 466.0 k | 936.0 k | SEC (XBRL)· 30 Mar 2026verified |
| Current liabilities | 6.3 m | 51.2 m | 33.8 m | 32.8 m | 34.9 m | 34.0 m | SEC (XBRL)· 30 Mar 2026verified |
| Total liabilities | 25.5 m | 82.4 m | 36.9 m | 35.1 m | 36.0 m | 35.4 m | SEC (XBRL)· 30 Mar 2026verified |
| Equity | 12.6 m | 204.9 m | 23.8 m | 13.7 m | 3.1 m | -3.6 m | SEC (XBRL)· 30 Mar 2026verified |
| Shares outstanding at year end | 159.1 m | 68.2 m | 7.6 m | 13.4 m | 3.1 m | 5.9 m | SEC (XBRL)· 30 Mar 2026verified |
Cash flow · CAD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -7.9 m | -34.4 m | -12.6 m | -8.1 m | -1.1 m | 4.7 m | SEC (XBRL)· 30 Mar 2026verified |
| Capex | 2.6 m | 4.6 m | 1.6 m | 581.0 k | 156.0 k | 13.0 k | SEC (XBRL)· 30 Mar 2026verified |
| Free cash flow | -10.5 m ≈ | -39.0 m ≈ | -14.2 m ≈ | -8.7 m ≈ | -1.2 m ≈ | 4.7 m ≈ | SEC (XBRL)· 30 Mar 2026derived |
| Investing cash flow | -4.1 m | -9.0 m | -1.5 m | -1.2 m | -470.0 k | -531.0 k | SEC (XBRL)· 30 Mar 2026verified |
| Financing cash flow | 6.7 m | 48.7 m | 4.8 m | 9.4 m | 3.8 m | 1.1 m | SEC (XBRL)· 30 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 4 of at least 6
- score weight coverage: 25.0% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: unavailable
Price and reporting are in different currencies; market indicators are unavailable.
Key indicators
Coverage and freshness
Score by group
25% · Insufficient data
Estimated value range
unavailable — no valuation assumptions for the reporting currency
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 6.5%
- Equity risk premium
- 6.0%
- Beta (default)
- 1.00
- Cost of equity
- 12.5%
- Terminal growth
- 3.0%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 4 of at least 6; score weight coverage: 25.0% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -20.7% | 20 (vs peers) | 25% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 0.2% | 2 (on a fixed band) | 33% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -3.3x | 0 (on a fixed band) | 25% |
| Current ratio · Balance sheet | 0.7x | 0 (on a fixed band) | 17% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet0/100 · 2/3 factors with a value
- Growth· partial2/100 · 1/2 factors with a value
- Quality· partial20/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partialunavailable · 0/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
IM Cannabis Corp. (IMCC). Latest full fiscal year: 2025; data up to 2025-12-31.
Figures computed from the financial statements: revenue 54.7 m CAD in 2025; YoY growth 1.3%; net margin -20.7%; ROE -1,496.2%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 4 of at least 6; score weight coverage: 25.0% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
No signal among the computed factors. That is not an absence of risk: factors without data were not assessed, and business risks (margins, inventory, demand) are in the source-based analysis.
What contradicts it
- Net margin: -20.7%
- Revenue CAGR 3Y: 0.2%
- Interest coverage: -3.3x
- Current ratio: 0.7x
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, FCF yield, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Medicinal Chemicals & Botanical Products (SIC 2833) · same industry (4-digit SIC) · compared with 15 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| TRLVTrulieve Cannabis Corp. | 2.2 bn | — | -48.2% | -41.8% | −0.4% | +115% / +109% |
| TLRYTilray Brands, Inc. | 437.5 m | — | -10.4% | -17.1% | +11.5% | −63% / −84% |
| USNAUsana Health Sciences, Inc. | 264.8 m | — | -4.2% | -2.4% | unavailable | −28% / −70% |
| NAGENiagen Bioscience, Inc. | 199.6 m | 21.3 | 13.3% | 8.4% | +29.9% | −63% / +81% |
| MDWDMediwound Ltd. | 182.3 m | — | -63.9% | -140.8% | −16.1% | −21% / +59% |
| FTLFFitlife Brands, Inc. | 76.8 m | 13.1 | 14.1% | 6.2% | +26.4% | −56% / −15% |
| BTMDbiote Corp. | 71.6 m | 11.8 | — | 3.2% | −2.5% | −55% / −75% |
| NAIINatural Alternatives International, Inc. | 24.3 m | — | -35.0% | -14.5% | +9.7% | −70% / −81% |
| MTEXMannatech Inc | 16.7 m | — | -1,490.1% | -6.9% | −8.3% | −8% / −3% |
| BONBon Natural Life Limited | 4.4 m | — | -3.9% | -10.7% | −21.7% | −39% / −99% |
| CRONCronos Group Inc. | — | — | 6.5% | 39.1% | +24.6% | +42% / +74% |
| CGCCanopy Growth Corp | — | — | -39.9% | -79.2% | +5.8% | −36% / −87% |
| ACBAurora Cannabis Inc | — | — | 0.3% | 0.5% | +27.3% | +14% / +14% |
| GLASGlass House Brands Inc. | — | — | -31.2% | -16.3% | −9.4% | −57% / −45% |
| SNDLSNDL Inc. | — | — | -1.4% | -1.7% | +2.8% | −20% / −1% |
| IMCCIM Cannabis Corp. | — | — | -1,496.2% | -20.7% | +1.3% | −98% / −99% |
1- and 3-year price returns: for IMCC from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 30 Mar 2026; since then the company filed 6-K (04 Nov 2026), 6-K (02 Oct 2026), 6-K (28 Sept 2026), 6-K (25 Sept 2026), 6-K (24 Sept 2026), 6-K (23 Sept 2026).
In brief
IM Cannabis Corp. imports, distributes and sells medical cannabis to patients in Israel and Germany, using a cross-border supply chain. In 2025 Germany became the main market after the access reforms of April 2024, but the company still does not make a profit and continuing operations depends on additional funding. Total revenue was 54.7 million CAD 1, while the operating loss was 11.6 million USD 1.
SWOT
Strengths
- The company has an integrated import, distribution and sales infrastructure, with EU-GMP authorisations in Germany and its own pharmacies in Israel 1.
- The IMC brand has built a reputation over several years in Israel, and its premium brand portfolio gives it differentiation 1.
- Presence in two regulated markets allows geographic diversification of revenue 1.
Weaknesses
Opportunities
- Growth of the German market after the access reform could support expanded sales through Adjupharm 1.
- A possible liberalisation of Israeli regulation could widen the patient base served by its own pharmacies 1.
- Launching new strains and brands in both markets could strengthen pricing and sales volume 1.
Risks
- Going concern uncertaintyhigh
Management has indicated that conditions raise substantial doubt about the company's ability to continue as a going concern, and no adjustments are made for that case 1.
- No profitabilityhigh
The company has incurred operating losses every year and cannot predict when, or whether, it will become profitable 1.
- Israeli anti-dumping levieshigh
If the proposed levies on Canadian imports are imposed, the cost of goods sold could rise significantly 1.
- Geopolitical risk in Israelmedium
Armed conflict in the region can affect operations, discourage business partners and make it harder to raise capital 1.
- Credit and financing riskmedium
Credit facilities and loans in Israel carry covenants, and failing to meet them could trigger defaults 1.
Investment thesis
What would need to be true (bull case)
- If Germany keeps expanding after the access reform, Adjupharm could become a solid European hub with visible revenue growth 1.
- Its position as importer and pharmacy owner in Israel may give the company an advantage in accessing premium Canadian products 1.
- If cost reduction and operational efficiency deliver results, the company could narrow losses and obtain financing more easily 1.
What would break the thesis
- If anti-dumping taxes are imposed, margins in Israel could fall quickly and the company may have to cut prices 1.
- Continued losses and negative cash flow could force the company to issue new shares, with a dilutive effect 1.
- If the region stays unstable, logistical disruptions and the loss of partners could weigh on Israeli revenue 1.
What to watch
- Development of anti-dumping levies on Canadian imports2026
- German segment revenue and the pace of patient growthQ1 2027
- Clarification of going concern status and additional financingnext 10-K
- Trend in operating losses and cash flow2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 30 Mar 2026; since then the company filed 6-K (04 Nov 2026), 6-K (02 Oct 2026), 6-K (28 Sept 2026), 6-K (25 Sept 2026), 6-K (24 Sept 2026), 6-K (23 Sept 2026).
The business
IM Cannabis Corp. is an international cannabis company focused on importing, distributing and selling medical cannabis products to patients in Israel and Germany 1. In Israel it operates licensed pharmacies, online platforms and a distribution centre, while in Germany it works through its subsidiary Adjupharm GmbH, which distributes products to licensed pharmacies 1. After the CCAA proceedings in Canada ended, the company concentrated its activity on these two markets 1.
The company links its Israeli and German operations through a cross-border supply chain in which cannabis is imported, mainly from Canada, then packaged and distributed through its own infrastructure 1. Adjupharm holds EU-GMP authorisations for repackaging, stability testing and batch release, and its German logistics centre serves as the European hub 1.
The financial structure remains fragile: operating cash flow was negative in 2025 and the Board approved a cost saving plan, while the going concern uncertainty is flagged by management 1. To sustain operations, IM Cannabis relies on bank credit and on possible share issuances 1.
Segments
Germany
Germany is the fastest-growing segment, with revenue of 36.3 million CAD in 2025, compared with 15.5 million CAD in 2024 1. The growth reflects easier patient access to medical cannabis after the April 2024 reform and an expanded portfolio that includes the BLKMKT and Selected brands 1.
Israel
The Israeli segment fell to 18.4 million CAD in 2025 from 38.5 million CAD in 2024, reflecting the reduction of trading activities, restructuring and logistical disruptions linked to regional conflicts 1. The company holds two licensed pharmacies in Israel, Vironna and Pharm Yarok, which support its distribution activity 1.
Market context
The Israeli market is large and growing, with approximately 137,900 licensed medical patients as of February 2026, but it is becoming more competitive, and the ability to import premium Canadian cannabis is a key factor 1. The German market has developed more slowly, but the company observes more patients buying out of pocket, and expansion depends on the pace of regulation 1.
Management does not give a quantitative estimate of market size and stresses that the pace of expansion in Germany remains uncertain 1. The ability to obtain approvals and keep supplier access will largely determine whether these markets can support durable revenue growth 1.
Trends
- Growing patient numbers in Israeltailwind
The number of licensed patients keeps rising and could benefit from a possible liberalisation of regulation in Israel 1.
- German patient reformtailwind
The April 2024 reform eased patient access to medical cannabis, and expansion of this market could continue, although its pace remains uncertain 1.
- Israeli anti-dumping investigationheadwind
The inquiry into cannabis imports from Canada could lead to levies that raise the cost of goods sold for imported products, and the Ministry of Economy recommended a 175% tax for non-cooperative companies 1.
- Price and margin pressuremixed
The company must maintain its average selling price and margins, and rising competition in Israel and Germany could reduce those margins 1.
Competitive position
Competition is intense and mostly regional: in Israel the company faces other established medical cannabis brands and manufacturers, while in Germany Adjupharm competes with several licensed manufacturers and distributors, from well-capitalised multinationals to smaller new entrants 1.
Competitiveness shows in access to supply and in the ability to differentiate premium brands, and losing share in Israel could quickly affect revenue given the company's limited capital 1.
- Israeli medical cannabis brands and producers
Local brands and manufacturers that compete directly in the Israeli market 1.
- Licensed German manufacturers and distributors
Established operators and new entrants that compete with Adjupharm for distribution to pharmacies 1.
- Large medical cannabis multinationals
Companies with large-scale operations and revenues, described in the source as important competitors in Germany 1.
- Canadian cannabis suppliers
Supply partners that are also competitors for premium products imported into Israel and Germany 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report (foreign issuer)04 Nov 2026
- Current report (foreign issuer)02 Oct 2026
- Current report (foreign issuer)28 Sept 2026
- Current report (foreign issuer)25 Sept 2026
- Current report (foreign issuer)24 Sept 2026
- Current report (foreign issuer)23 Sept 2026
- Current report (foreign issuer)23 Sept 2026
- Current report (foreign issuer)02 Sept 2026
- Current report (foreign issuer)27 Aug 2026
- Current report (foreign issuer)18 Aug 2026
Sources
- [1] Form 20-F, fiscal year ended 2025-12-31 · SEC / IM Cannabis Corp. · 30 Mar 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.